H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

Homologous recombination deficiency and ovarian cancer

(2016) Jonathan A. Ledermann et al.   EUROPEAN JOURNAL OF CANCER

A Phase II study of olaparib in breast cancer patients: biological evaluation from a ‘window of opportunity’ trial

(2016) Giandomenico Roviello et al.   Future Oncology

Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer

(2016) Marta Truffi et al.   PHARMACOLOGICAL RESEARCH

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells

(2016) Shuhei Ito et al.   PLoS One

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

(2016) Philip C. Schouten et al.   Trials

Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and “BRCAness” Mutations

(2016) Sanghee Hong et al.   Journal of Oncology Practice

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

(2015) William Jacot et al.   Future Oncology

Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity

(2015) Joseph M. Caster et al.   Nanoscale

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

(2015) Fanny Le Du et al.   Oncotarget

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib

(2015) Robin Dufour et al.   Scientific Reports

H-Chain Ferritin: A Natural Nuclei Targeting and Bioactive Delivery Nanovector

(2015) Lianbing Zhang et al.   Advanced Healthcare Materials

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer

(2014) Lisa A. Newman et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting homologous recombination-mediated DNA repair in cancer

(2014) João FS Carvalho et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer Cells

(2014) Michela Bellini et al.   JOURNAL OF CONTROLLED RELEASE

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors

(2013) Zipeng Zhen et al.   ACS Nano

Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?

(2013) Roxana Chiorean et al.   BREAST

IRP2 Regulates Breast Tumor Growth

(2013) Wei Wang et al.   CANCER RESEARCH

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

(2013) Nigel Bundred et al.   INVESTIGATIONAL NEW DRUGS

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

(2012) Hsiao-Ching Chuang et al.   BREAST CANCER RESEARCH AND TREATMENT

Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1

(2012) N. Singh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The transferrin receptor and the targeted delivery of therapeutic agents against cancer

(2011) Tracy R. Daniels et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints

(2010) Conly L. Rieder   CHROMOSOME RESEARCH

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Management of breast cancer with targeted agents: importance of heterogenicity

(2010) Serena Di Cosimo et al.   Nature Reviews Clinical Oncology

Binding and uptake of H-ferritin are mediated by human transferrin receptor-1

(2010) Li Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protein-Based Nanomedicine Platforms for Drug Delivery

(2009) Aihui MaHam et al.   Small

Pharmacokinetics and Biodistribution of Nanoparticles

(2008) Shyh-Dar Li et al.   MOLECULAR PHARMACEUTICS